Silo pharma enters into exclusive license agreement with medspray pharma bv for intranasal technology used in spc-15 treatment for ptsd

Medspray's patented nose-to-brain intranasal technology selected for spc-15 drug delivery exclusivity covers multiple indications including anxiety disorders, alzheimer's disease, and anorexia englewood cliffs, nj, nov. 21, 2023 (globe newswire) -- silo pharma, inc. (nasdaq: silo) (“silo” or “the company”), a developmental stage biopharmaceutical company focused on merging traditional therapeutics with psychedelic research, today announced a new exclusive license agreement with medical technology manufacturer medspray pharma bv for its proprietary patented soft mist nasal spray technology, the delivery mechanism selected for silo's intranasal therapeutic drug spc-15. “we began a collaboration with medspray earlier this year for feasibility studies evaluating its patented technology as a delivery mechanism for our intranasal therapeutic drug spc-15.
SILO Ratings Summary
SILO Quant Ranking